2022-502850-14-00招募中1 期
A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
Prelude Therapeutics Inc.11 个研究点 分布在 4 个国家目标入组 70 人开始时间: 2023年8月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
- 试验地点
- 11
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Medical Lead
Scientific
Prelude Therapeutics Inc.
研究点 (11)
Loading locations...
相似试验
终止
3 期
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective TrialNCT06828861Aardvark Therapeutics, Inc.68
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD TherapyMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic ArthritisEUCTR2019-002021-29-ESGilead Sciences Inc.390
进行中（未招募）
3 期
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative ColitisCTRI/2023/05/052724Johnson and Johnson Private Limited
进行中（未招募）
1 期
A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary arterial hypertension (PAH) Patients.Pulmonary Arterial Hypertension (PAH)MedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-000199-12-DEAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA444
招募中
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)EUCTR2020-003084-26-FRChinook Therapeutics U.S., Inc.320